Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Clinical trial NCT07492342 · RECRUITING

Trial details

NCT number: NCT07492342
Sponsor: Jianxing He
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable NSCLC KRAS G12C Mutation Stage IB-IIIA NSCLC Neoadjuvant Therapy

Start date: 2026-01-29
Primary completion: 2027-03-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.